a public good project by the
Synthesis
Company
of California

© 2026

Changchun Deng | doi.page

0 works0 citations0 h-index

Changchun Deng

Qinghai University(CN)Huaqiao University(CN)University Hospitals of Cleveland(US)University Hospitals of Cleveland(US)University Hospitals Seidman Cancer Center(US)

Publications by Year

Research Areas

Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Histone Deacetylase Inhibitors Research, Viral-associated cancers and disorders, PI3K/AKT/mTOR signaling in cancer

Most-Cited Works

→ Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study(2018)204 cited
→ Integrating phenotypic and expression profiles to map arsenic-response networks(2004)183 cited
→ Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study(2020)176 cited
→ Global analysis of gene function in yeast by quantitative phenotypic profiling(2006)174 cited
→ Brentuximab Vedotin(2012)145 cited
→ A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma(2017)133 cited

→ The Saccharomyces cerevisiae Kinesin-related Motor Kar3p Acts at Preanaphase Spindle Poles to Limit the Number and Length of Cytoplasmic Microtubules(1997)

130 cited

→ Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study(2019)127 cited

→ Identification of Mitogen-Activated Protein Kinase Signaling Pathways That Confer Resistance to Endoplasmic Reticulum Stress in Saccharomyces cerevisiae(2005)123 cited

→ Multiple Endonucleases Function to Repair Covalent Topoisomerase I Complexes in Saccharomyces cerevisiae(2005)116 cited